[ad_1]
Phase 3 trials of the oral nonpeptide show glycemic and weight benefit when added to glargine and compared with dapagliflozin and oral semaglutide, but with somewhat lower tolerability.
Medscape Medical News
[ad_2]
Source link : https://www.medscape.com/viewarticle/oral-glp-1-orforglipron-performs-well-phase-3-t2d-trials-2026a1000jfv?src=rss
Author :
Publish date : 2026-06-10 13:30:00
Copyright for syndicated content belongs to the linked Source.